ChiCTR1800014883
结束
/
/
/
2018-02-12
/
/
血脂异常
紅麴治療高血脂症的隨機對照研究
紅麴治療高血脂症的隨機對照研究
110
Red yeast rice (RYR) has been used as an alternative treatment for hyperlipidemia recently. According to the previous study, other compounds, besides monacolin k in RYR, may also have efficacy on serum lipid improvement. This study aims at examining the efficacy of monacolin k-rich and Gamma-Aminobutyric Acid (GABA)-rich red yeast rice (Monascus pilosus) regarding treating hyperlipidemia on a randomized control, double-blind clinical trial.
随机平行对照
其它
Randomization was done by a trial administrator who was not involved in the clinical intervention or evaluation using computer-generated random sequence after participants enrolled in this study before administrating medications.The random sequences evenly distributed all participants to three study arms.
All doctors, pharmacists, project managers, statisticians and participants in this research were blinded to the allocation sequence throughout the entire trial phase.
Grand of Chang Gung University Center for Industry Sponsored Research and Collaborations SCRPD1A0011
/
23
/
2011-04-01
2013-10-31
/
Before the exclusion were interviewed by internal medicinal physicians at Chang-Gung Memorial hospital in a preliminary screening, subjects met the criteria (LDL >100 mg/dl, TC > 200 mg/dl) will be included.；
请登录查看Some subjects were excluded from the study due to the following factors: 1) take hormone replacement therapy or immunosuppressive agents, 2) take the lipid-regulating drugs, 3) take the drugs known to affect lipid concentrations, 4) take the drugs known to be associated with rhabdomyolysis, cardiovascular disease, severe systemic and chronic disease, malignant neoplasm, 5) pregnancy, 6) receive insulin or oral hypoglycemic agents 7) have an endocrine disease related to lipid abnormalities.；
请登录查看development department, Gunze Limited, Japan
110
development department, Gunze Limited, Japan的其他临床试验
長庚紀念醫院的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04